Diastereoselective Synthesis of Octahedral Cationic Iridium Hydride Complexes with a Stereogenic Metal Centre

by

Nicolas Humbert and Clément Mazet*

Department of Organic Chemistry, University of Geneva, 30 quai Ernest Ansermet, 1211 Geneva, Switzerland.

Email: clement.mazet@unige.ch

General information

Commercial reagents were purchased from Sigma-Aldrich, Acros Organics or Strem Chemicals and used without purification unless otherwise noted. Air sensitive compounds such as phosphines or metal complexes were stored under inert atmosphere inside a MBraun glovebox. Solvents were dried over activated alumina columns and further degassed by three successive "freeze-pump-thaw" cycles if necessary. Oxazoline ligands $2a-d_{1}^{1}$ [Ir(cod)Cl]₂² and NaBAr_F³ were prepared according to literature procedures. All reactions were carried out under an inert atmosphere of nitrogen using either two-manifold vacuum/inert gas lines or a MBraun glovebox unless otherwise noted. Flash chromatography was performed using silica gel 60 (230-400 mesh) from Silicycle. ¹H, ³¹P{¹H}, ¹⁹F{¹H} and ¹³C{¹H} spectra were recorded on ARX-300, ARX-400 and ARX-500 Bruker Avance spectrometers. ¹H and ¹³C NMR chemical shifts are given in ppm relative to SiMe₄, with the solvent resonance used as internal reference. ³¹P NMR chemical shifts are reported in ppm relative to H₃PO₄. ¹⁹F NMR chemical shifts are reported in ppm relative to CFCl₃. Data are reported as follows: chemical shift, multiplicity (b = broad, s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet), coupling constant (Hz) and integration. Melting points were measured on a Büchi Melting Point M-565. Infrared spectra were recorded on a Perkin-Elmer Spectrum 100 spectrometer using neat samples on a diamond ATR Golden Gate sampler. Optical rotations were measured on a Jasco P-1030 polarimeter equipped with a Na-lamp and are reported as follows: $[\alpha]^{T}_{D}$, concentration (g.mL⁻¹) and solvent. MALDI spectra were measured using a Brucker Daltonics Autoflex TOF spectrometer.

Synthesis of [Ir((S,S)-bod*)Cl]₂



In a Schlenk equipped with a J-Young-valve, (15,4S)-2,5-diphenyl-bicyclo-[2.2.2]-octa-2,5-diene (bod*) (1.0 eq., 0.1 mmol) was added to a solution of $[Ir(coe)_2Cl]_2$ (0.5 eq., 0.05 mmol) in degassed hexane (1.0 mL, 0.1 M) at 23 °C. The Schlenk was sealed and placed in a preheated oil bath (50 °C) and stirred for 48 hours. The reaction was cooled to room temperature. The red precipitate obtained

was isolated by filtration and washed with a small amount of hexanes to yield in analytically pure form (68% yield). All analyses were in agreement with those reported in the literature.⁴

Synthesis of ⊿-4



In a Schlenk equipped with a J-Young-valve, 8-methylquinoline (1.0 eq., 7.0 µL, 0.051 mmol) was added to a solution of **2** (0.5 eq., 25 mg, 0.026 mmol) in degassed CH_2CI_2 (1.0 mL, 0.025 M) at 23 °C. The reaction was stirred for one hour and then brought into a glove box. Trimethylphosphine (1.0 eq., 5.3 µL, 0.051 mmol) was then added in one portion and the resulting solution stirred for one hour under inert atmosphere. Outside of the glove box, in open-air, NaBAr_F (1.0 eq., 47 mg, 0.51 mmol) was added to the mixture and the resulting suspension vigorously stirred for 15 hours at 70 °C. The reaction was cooled down to room temperature before evaporation of the solvent under reduced pressure. The crude mixture was purified by column chromatography (eluent: CH_2CI_2 ; $R_f = 0.9$). A purple, air-stable solid was obtained (56 mg, 70% yield). The product was obtained along with ca. 10% of $[Ir(cod)_2]BAr_F$.



⊿-4

Purple solid. **Yield** = 70% (90% purity). *dr* >30:1

¹**H NMR** (400 MHz, CDCl₃, 298 K): δ (ppm) = 9.42 (d, ³J_{HH} = 4.9 Hz, 1H, H-9), 8.13 (dd, ³J_{HH} = 8.2 Hz, ⁴J_{HH} = 1.0 Hz, 1H, H-11), 7.73 (m, 9H, *o*-H_{BArF}, H_{Ph-b}), 7.52 (m, 4H, *p*-H_{BArF}), 7.48 (dd, ³J_{HH} = 8.2 Hz, ⁴J_{HH} = 5.0 Hz, 1H, H-10), 7.38–7.45 (m, 4H, H_{Ph-b}), 7.25 (m, 1H, H-12), 7.21 (m, 2H, H-13,14), 6.66 (m, 1H, H_{Ph-a}), 6.50 – 6.60 (m, 4H, H_{Ph-a}), 5.59 (ddd, ³J_{HH} = 6.0 Hz, ⁴J_{HH} = 3.0 Hz, ⁴J_{HH} = 1.0 Hz, 1H, H-1), 4.65 (m, 1H, H-6), 4.59 (m, 2H, H-3,4), 3.23 (dd, ²J_{HH} = 16.9 Hz, ³J_{HP} = 7.5 Hz, 1H, H-18), 2.61 (d, ³J_{HP} = 16.8 Hz, 1H, H-18), 1.47–1.52 (m, 1H, H-8), 1.34–1.39 (m, 1H, H-8), 1.17–1.23 (m, 2H, H-7), 0.57 (d, ²J_{HP} = 10.9 Hz, 9H, H_{PMe3}) [for the other isomer: 0.98 (d, ²J_{HP} = 10.6 Hz, 9H, H_{PMe3})], -15.86 (d, ²J_{HP} = 15.4 Hz, 1H, Ir–H) [for the other isomer: -16.46 (d, ²J_{HP} = 20.8 Hz, 1H, Ir–H).].

¹³C{¹H} NMR (100 MHz, CDCl₃, 298 K): δ (ppm) = 161.70 (1:1:1:1 patern, ¹*J*_{CB} = 49.5 Hz, *ipso*-C-B_{BArF}), 152.37 (s, C-9), 150.03 (s, C-16), 148.68 (s, C-15), 139.04 (s, C-11), 136.66 (s, C^{IV}_{Ph-b}), 134.80 (bs, *o*-C_{BArF}), 132.84 (s, C-14), 129.98 (s, C-17), 129.61 (s, C_{Ph-b}), 129.28 (s, 2C_{Ph-b}), 129.11 (s, C_{Ph-a}), 128.91 (qq, ²*J*_{CF} = 31.4 Hz, ⁵*J*_{CF} = 2.8 Hz, *m*-C_{BArF}), 128.65 (s, C-13), 128.47 (s, C^{IV}_{Ph-a}), 127.67 (s, 2C_{Ph-a}), 126.26 (s, C_{Ph-b}), 124.91 (s, C-12), 124.54 (q, ¹*J*_{CF} = 270.9 Hz, C_{CF3}), 123.53 (bs, 2C_{Ph-a}), 123.02 (s, C-10), 117.38–117.54 (m, *p*-C_{BArF}), 97.04 (s, C-5), 95.59 (d, ²*J*_{CP} = 12.2 Hz, C-2), 72.49 (d, ²*J*_{CP} = 11.3 Hz, C-1), 64.24 (s, C-4), 47.77 (d, ³*J*_{CP} = 0.8 Hz, C-6), 36.60 (d, ³*J*_{CP} = 2.4 Hz, C-3), 30.73 (d, ⁴*J*_{CP} = 2.3 Hz, C-6), 28.86 (d, ³*J*_{CP} = 1.5 Hz, C-7), 13.97 (d, ¹*J*_{CP} = 40.5 Hz, C_{PMe3}), 7.65 (d, ²*J*_{CP} = 4.4 Hz, C-18). ³¹P{¹H} NMR (162 MHz, CDCl₃, 298 K): δ = -30.81 [for the minor isomer: -35.49] ¹⁹F{¹H} NMR (282 MHz, CDCl₃, 298 K): δ = -61.61 (s). HR-MS (MALDI TOF) C₃₃H₃₆IrNP [M]⁺: 670.221, found 670.319. IR: v [cm⁻¹] = 1354, 1274, 1121, 952, 885, 837, 713, 676. [*α*]²⁰_D: +14.2 (c 0.1, CH₂Cl₂). T _{decomp}: 55 °C.

General procedure for the synthesis of iridium hydride complexes with ligands 2a,c-d



General procedure: In a Schlenk equipped with a J-Young-valve, the appropriate oxazoline precursor (1.0 eq., 0.15 mmol) was added to a solution of $[Ir(cod)Cl]_2$ (0.5 eq., 50 mg, 0.07 mmol) in degassed CH₂Cl₂ (3.0 mL, 0.025 M) at 23 °C. The reaction was stirred for one hour and then brought into a glove box. The phosphine (1.0 eq., 0.15 mmol) was then added in one portion and the resulting solution stirred for one hour under inert atmosphere. Outside of the glove box, in open-air, NaBAr_F (1.0 eq., 139 mg, 0.16 mmol) was added to the mixture and the resulting suspension vigorously stirred for 15 hours at 70 °C. After evaporation of the solvent under reduced pressure, the crude mixture was purified by column chromatography (CH₂Cl₂:pentane 1:1).



Entry	Ligand	R^1	R ²	R₃P	T (°C)	Products	Yield (%)	<i>dr</i> (Λ:Δ) ^{a,b}
1	(R)- 5 a	Ph	Ph	Cy₃P	70	(R)-∆-6a/(R)-∆-6a	nr ^c	-
2	(R)- 5 a	Ph	Ph	$Me_{3}P$	23	(R)-∆-6a/(R)-∆-6a	43	1.4:1 (2.9:1)
3	(R)- 5 a	Ph	Ph	Me₃P	70	(R)- ∆-6a/(R)-∆-6a	78	5.5:1 (12:1)
4	(R)- 5b	Ph	<i>t</i> -Bu	Me₃P	70	(R)-∆- 6b/ (R)-∆- 6b	nr	-
5	(S)- 5c	<i>i</i> -Pr	Ph	Me ₃ P	23	(R)-∆-6c/(R)-∆-6c	65	2.7:1
6	(S)- 5c	<i>i</i> -Pr	Ph	Me_3P	70	(<i>R</i>)-∆-6c/(<i>R</i>)-∆-6c	86	1:9
7	(S)- 5d	<i>t</i> -Bu	Ph	Me₃P	23	(R)-∆-6d/(R)-∆-6d	57	1:>30
8	(S)- 5d	<i>t-</i> Bu	Ph	Me₃P	70	(R)-∆-6d/(R)-∆-6d	96	1:>30

^a Determined by ¹H NMR of the crude reaction mixture. ^b The ratio in brackets was obtained after purification by column chromatography. ^c *nr* = no reaction.



(R)-Л-6a

Light-brown solid.

Yield = 78%.

dr 5.5:1 (crude); 12:1 (after column)

¹**H NMR** (400 MHz, CDCl₃, 298 K): δ (ppm) = 7.70 (m, 8H, *o*-H_{BArF}), 7.52 (m, 6H, H-13,16, *p*-H_{BArF}), 7.40 (s, 5H, H_{Ph}), 7.24 (ddd, ³*J*_{HH} = 7.4 Hz, ³*J*_{HH} = 7.4 Hz, ⁴*J*_{HH} = 1.1 Hz, 1H, H-15), 7.17 (t, ³*J*_{HH} = 7.6 Hz, 1H, H-14), 5.37 (dd, ³*J*_{HH} = 10.0 Hz, ³*J*_{HH} = 4.4 Hz, 1H, H-9), 5.24 (dd, ²*J*_{HH} = 9.6 Hz, ³*J*_{HH} = 9.6 Hz, 1H, H-10), 5.12 (dd, ²*J*_{HH} = 9.4 Hz, ³*J*_{HH} = 4.2 Hz, 1H, H-10), 4.99 (m, 1H, H-1), 4.53 (m, 1H, H-5), 4.46 (m, 1H, H-4), 3.46 (m, 1H, H-8), 3.16 (dd, ²*J*_{HH} = 14.4 Hz, ³*J*_{HH} = 8.0 Hz, 1H, H-3), 2.87 (m, 1H, H-7), 2.67 (m, 1H, H-6), 2.40–2.59 (m, 3H, H-2,3,7), 2.08 (m, 1H, H-6), 1.81 (m, 1H, H-2), 0.69 (d, ²*J*_{HP} = 10.4 Hz, 9H, H_{PMe3}), – 15.90 (d, ²*J*_{HP} = 15.6 Hz, 1H, Ir–H). [for the minor isomer: –16.58 (d, ²*J*_{HP} = 14.8 Hz, 1H, Ir–H).] ¹³C{¹H} NMR (100 MHz, CDCl₃, 298 K): δ (ppm) = 178.59 (s, C-11), 161.68 (1:1:1:1 pattern, ¹*J*_{CB} = 49.6 Hz, *ipso*-C_{BArF}), 153.03 (d, ²*J*_{CP} = 8.6 Hz, C-17), 139.78 (s, C-16), 139.45 (s, *ipso*-C_{Ph}), 135.29 (s, C-15), 134.79 (bs, *o*-C_{BArF}), 130.13 (s, *o*-C_{Ph}), 129.10 (s, C-13), 129.09 (s, C-12), 128.88 (qq, ²*J*_{CF} = 31.3 Hz, ⁵*J*_{CF}

= 2.9 Hz, m-C_{BArF}), 127.82 (s, m-C_{Ph}), 127.01 (s, p-C_{Ph}), 124.53 (q, ${}^{1}J_{CF}$ = 270.9 Hz, C_{CF3}), 124.15 (s, C-14), 117.41–117.49 (m, p-C_{BArF}), 95.77 (d, ${}^{2}J_{CP}$ = 10.5 Hz, C-1), 93.55 (d, ${}^{2}J_{CP}$ = 15.1 Hz, C-8), 87.31 (s, C-4),

80.23 (s, C-5), 78.45 (s, C-10), 69.35 (s, C-9), 36.89 (d, ${}^{4}J_{CP} = 3.5$ Hz, C-3), 31.51 (d, ${}^{3}J_{CP} = 1.9$ Hz, C-7), 28.53 (s, C-2), 27.30 (d, ${}^{4}J_{CP} = 2.8$ Hz, C-6), 14.54 (d, ${}^{1}J_{CP} = 40.1$ Hz, C_{PMe3}). ³¹P{¹H} NMR (162 MHz, CDCl₃, 298 K): $\delta = -36.60$ (bs). [for the minor isomer: -33.59 (bs).] ¹⁹F{¹H} NMR (282 MHz, CDCl₃, 298 K): $\delta = -61.63$ (s). HR-MS (MALDI TOF) C₂₆H₃₄IrNOP [M]⁺: 600.200, found 600.366. IR: v [cm⁻¹] = 3282, 2947, 2222, 1613, 1550, 1484, 1460, 1406, 1354, 1272, 1159, 1116, 1047, 946, 887, 837, 761, 740, 710, 680, 668. [α]²⁰_D: -51.3 (c 1.0, CH₂Cl₂). T.dec.: 147 °C.



¹**H NMR** (400 MHz, CDCl₃, 298 K): δ (ppm) = 7.70 (m, 8H, *o*-H_{BArF}), 7.53 (m, 6H, H-13,16, *p*-H_{BArF}), 7.24 (ddd, ${}^{3}J_{HH} = 7.6$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, ${}^{4}J_{HH} = 1.5$ Hz, 1H, H-15), 7.13 (t, ${}^{3}J_{HH} = 7.6$ Hz, 1H, H-14), 5.02 (m, 1H, H-1), 4.83 (dd, ${}^{2}J_{HH} = 9.6$ Hz, ${}^{3}J_{HH} = 5.2$ Hz, 1H, H-10), 4.76 (t, ${}^{2}J_{HH} = 9.6$ Hz, ${}^{3}J_{HH} = 5.2$ Hz, 1H, H-10), 4.65 (m, 1H, H-4), 4.58 (m, 1H, H-5), 4.40 (ddd, ${}^{3}J_{HH} = 9.6$ Hz, ${}^{3}J_{HH} = 5.2$ Hz, 1H, H-9), 3.40 (m, 1H, H-8), 2.93 (m, 1H, H-3), 2.38 – 2.66 (m, 5H, H-2,3,6,7,7), 2.19 (m, 1H, H-6), 2.03 (m, 2H, H-2, CH_{*i*-*p*-</sup>), 1.21 (d, ${}^{2}J_{HP} = 10.4$ Hz, 9H, H_{PMe3}), 1.06 (d, ${}^{3}J_{HH} = 7.2$ Hz, 3H, H_{*i*-Pr}), 0.88 (d, ${}^{3}J_{HH} = 6.8$ Hz, 3H, H_{*i*-Pr}), -15.85 (d, ${}^{2}J_{HP} = 17.2$ Hz, 1H, Ir–H). [for the minor isomer: -16.34 (d, ${}^{2}J_{HP} = 14.4$ Hz, 1H, Ir–H).] ¹³C{¹H} NMR (100 MHz, CDCl₃, 298 K): δ (ppm) = 178.72 (s, C-11), 161.68 (1:1:1:1 pattern, ${}^{1}J_{CB} = 49.5$ Hz, *ipso*-C_{BArF}), 151.95 (d, ${}^{2}J_{CP} = 8.9$ Hz, C-17), 139.80 (s, C-16), 135.09 (s, C-15), 134.77 (bs, *o*-C_{BArF}), 129.41 (s, C-12), 129.26 (s, C-13), 128.88 (qq, ${}^{2}J_{CF} = 31.3$ Hz, ${}^{5}J_{CF} = 2.8$ Hz, *m*-C_{BArF}), 124.53 (q, ${}^{1}J_{CF} = 270.9$ Hz, C_{CF3}), 124.17 (s, C-14), 117.38–117.54 (m, *p*-C_{BArF}), 96.37 (d, ${}^{2}J_{CP} = 10.1$ Hz, C-1), 94.27 (d, ${}^{2}J_{CP} = 15.8$ Hz, C-8), 87.17 (s, C-4), 81.05 (s, C-5), 70.49 (s, C-10), 70.36 (s, C-9), 35.43 (d, {}^{4}J_{CP} = 3.3 Hz, C-3), 30.50 (s, *C*H_{*i*-*P*}), 30.44 (d, ${}^{3}J_{CP} = 2.0$ Hz, C-7), 30.16 (d, ${}^{3}J_{CP} = 0.9$ Hz, C-2), 28.16 (d, ${}^{3}J_{CP} = 3.3$ Hz, C-3), 30.50 (s, *C*H_{*i*-*P*}), 30.44 (d, ${}^{3}J_{CP} = 2.0$ Hz, C-7), 30.16 (d, ${}^{3}J_{CP} = 0.9$ Hz, C-2), 28.16 (d, ${}^{3}J_{CP} = 3.3$ Hz, C-3), 30.50 (s, *C*H_{*i*-*P*}), 30.44 (d, ${}^{3}J_{CP} = 2.0$ Hz, C-7), 30.16 (d, ${}^{3}J_{CP} = 0.9$ Hz, C-2), 28.16 (d, ${}^{3}J_{CP} = 3.3$ Hz, C-3), 30.50 (s, *C*H_{*i*-*P*}), 30.44 (d,}}}

6), 20.40 (s, Me_{*i*-Pr}), 15.67 (d, ¹J_{CP} = 39.8 Hz, C_{PMe3}), 14.86 (s, Me_{*i*-Pr}).

³¹P{¹H} NMR (162 MHz, CDCl₃, 298 K): δ = -38.02 (bs). [for the minor isomer: -33.00 (bs).]

¹⁹F{¹H} NMR (282 MHz, CDCl₃, 298 K): δ = -61.62 (s).

HR-MS (MALDI TOF) C₂₃H₃₆IrNOP [M]⁺: 566.216, found 566.352.

IR: v [cm⁻¹] = 2966, 2239, 1616, 1548, 1461, 1393, 1354, 1272, 1159, 1116, 1047, 951, 887, 838, 739, 713, 681, 668.

[α]²⁰_D: +50.3 (c 1.0, CH₂Cl₂).

T_{decomp}: 162 °C.



(*S*)-∆-6d

Light-brown solid. Yield = 96%.

dr >30:1

¹**H NMR** (400 MHz, CDCl₃, 298 K): δ (ppm) = 7.70 (m, 8H, *o*-H_{BArF}), 7.52 (m, 6H, H-13,16, *p*-H_{BArF}), 7.27 (ddd, ³*J*_{HH} = 7.2 Hz, ³*J*_{HH} = 7.2 Hz, ⁴*J*_{HH} = 0.8 Hz, 1H, H-15), 7.14 (t, ³*J*_{HH} = 7.6 Hz, 1H, H-14), 5.01 (m, 1H, H-1), 4.95 (dd, ²*J*_{HH} = 9.6 Hz, ³*J*_{HH} = 2.8 Hz, 1H, H-10), 4.88 (m, 1H, H-4), 4.70 (m, 1H, H-5), 4.67 (dd, ²*J*_{HH} = 9.2 Hz, ³*J*_{HH} = 9.2 Hz, 1H, H-10), 4.05 (dd, ³*J*_{HH} = 9.0 Hz, ³*J*_{HH} = 2.6 Hz, 1H, H-9), 3.32 (m, 1H, H-8), 2.83 (m, 1H, H-3), 2.34–2.66 (m, 5H, H-2,3,6,7,7), 2.24 (m, 1H, H-6), 2.08 (m, 1H, H-2), 1.33 (d, ²*J*_{HP} = 10.4 Hz, 9H, H_{PMe3}), 1.04 (s, 9H, H_{t-Bu}), -17.55 (d, ²*J*_{HP} = 18.8 Hz, 1H, Ir–H).

¹³C{¹H} NMR (100 MHz, CDCl₃, 298 K): δ (ppm) = 180.39 (s, C-11), 161.69 (1:1:1:1 pattern, ¹J_{CB} = 49.2 Hz, *ipso*-C_{BArF}), 150.15 (d, ²J_{CP} = 9.5 Hz, C-17), 140.15 (s, C-16), 134.98 (s, C-15), 134.77 (bs, *o*-C_{BArF}), 130.10 (s, C-12), 129.50 (s, C-13), 128.89 (qq, ²J_{CF} = 31.3 Hz, ⁵J_{CF} = 2.8 Hz, *m*-C_{BArF}), 124.53 (q, ¹J_{CF} = 270.9 Hz, C_{CF3}), 124.19 (s, C-14), 117.38–117.53 (m, *p*-C_{BArF}), 98.38 (d, ²J_{CP} = 10.0 Hz, C-1), 96.77 (d, ²J_{CP} = 15.9 Hz, C-8), 89.92 (s, C-4), 84.21 (s, C-5), 74.07 (s, C-9), 73.26 (s, C-10), 35.20 (s, C^{IV}_{t-Bu}), 35.03 (d, ⁴J_{CP} = 3.1 Hz, C-3), 30.38 (d, ³J_{CP} = 1.1 Hz, C-2), 30.10 (d, ³J_{CP} = 2.0 Hz, C-7), 28.02 (d, ⁴J_{CP} = 3.3 Hz, C-6), 26.19 (s, Me_{t-Bu}), 15.65 (d, ¹J_{CP} = 40.1 Hz, C_{PMe3}).

³¹P{¹H} NMR (162 MHz, CDCl₃, 298 K): $\delta = -38.69$ (bs)

¹⁹F{¹H} NMR (282 MHz, CDCl₃, 298 K): δ = -61.61 (s).

HR-MS (MALDI TOF) C₂₄H₃₈IrNOP [M–COD]⁺: 472.138, found 471.981.

IR: v [cm⁻¹] = 2969, 2260, 1610, 1547, 1486, 1395, 1354, 1272, 1159, 1117, 1047, 949, 887, 838, 740, 713, 681, 668.

 $[\alpha]^{20}_{D}$: +57.7 (c 1.0, CH₂Cl₂).

T_{decomp}: 163 °C.

Inversion of configuration at the metal-centre

A J-Young-valve NMR tube was charged with the appropriate iridium complex (20 mg). Next, 1.0 mL of CDCl₃ was added at room temperature. The tube was then placed into a pre-heated oil bath (70 °C). The mixture was cooled to room temperature before recording ¹H NMR experiments periodically to quantify the ratio between the two diastereoisomers.



Entry	t (h)	dr ^a <i>(/</i> \:/
1	0	2.9:1
2	15	7.8:1
3	35	16.4:1
4	55	19.5:1
5	123	24.3:1
6	143	25:1

^a Determined by ¹H NMR.

В



Entry	t (h)	dr ^a <i>(/</i> \:/
1	0	2.7:1
2	15	1:7.2
3	35	1:10.7
4	55	1:11.3
5	123	1:11.3

¹ Determined by ¹H NMR.

Key nOe contacts in (S)- Δ -4



Sections of the NOESY spectrum for (S)- Δ -6d



Reaction of *rac*-1 (PF₆) with chiral anions analysed by ¹H NMR



¹H NMR: δ (CDCl₃) = -15.97 ppm (d, J = 16.2 Hz)

Entry	X(N <i>n</i> -Bu₄)	Solvent	Observation in ¹ H NMR
1	⊿-TRISPHAT	CDCl ₃	No change
2	∆-(S)- BINPHAT	CDCl ₃	δ = -16.01 ppm (d, J = 16.4 Hz); -16.02 ppm (d, J = 15.6 Hz)
3	⊿-TRISPHAT	toluene-d ₈	No change
4	∆-(S)- BINPHAT	toluene-d ₈	δ = –16.30 ppm (m)



Attempt to synthesise an analogue of complex 1 using a chiral monodentate *binepine* ligand



References

- 1) S. Nanchen and A. Pfaltz, *Chem. Eur. J.*, 2006, **12**, 4550.
- 2) J. Choudhury, S. Podder and S. Roy, J. Am. Chem. Soc., 2005, **127**, 6162.
- 3) D. L. Reger, T. D. Wright, C. A. Little, J. J. S. Lamba and M. D. Smith, *Inorg. Chem.*, 2001, **40**, 3810.
- 4) T. Nishimura, Y. Yasuhara, T. Sawano and T. Hayashi, J. Am. Chem. Soc., 2010, **132**, 7872.

NMR data for all new compounds



































